Abstract 828P
Background
Neurologic paraneoplastic syndromes (NPS) due to Hodgkin lymphoma (HL) affect both the central nervous system (CNS) and peripheral nervous system (PNS) with wide-ranging manifestations, such as limbic encephalitis, cerebellar degeneration, and neuropathies. We summarize the clinical findings and outcomes of 23 patients with HL associated with NPS.
Methods
Medical charts of adult patients at Mayo Clinic were retrospectively analyzed based on common endpoints and clinical features. Clinical diagnosis of NPS was made utilizing established criteria by Graus et al (Neurol Neuroimmunol Neuroinflamm, 2021). Survival analysis was performed using Kaplan-Meier estimates.
Results
We analyzed 23 patients with HL with NPS seen at Mayo Clinic from 1995 to 2022. Baseline disease included 17 patients with classical HL and 6 patients with nodular lymphocyte-predominant HL. Median follow-up was 97.1 months (95% CI 66.3-150.3). Baseline demographics included mean age 40 years with 61% males and 87% Caucasian patients. CNS PS was seen in 17 patients. Death had occurred in 5 patients at the time of review, including 4 without PS resolution, although no patients died from PS. NPS was the presenting sign of HL relapse in 39% patients. Following HL treatment, PS relapse was observed in 2 of 5 patients with prior complete PS resolution, temporally linked to HL relapse. Median overall survival (mOS) in patients with no PS improvement was 38.4 months, whereas mOS could not be reached in patients with complete/partial PS resolution (p=0.043). All 6 patients without PS improvement had CNS syndromes, whereas 3 of 5 patients with complete PS resolution had PNS disease. Paraneoplastic antibodies (anti-Tr most common) were detected in 7 of 21 tested patients without mortality or relapse associations. All 5 patients who experienced complete resolution of PS exhibited HL remission.
Conclusions
In our series of 23 patients with HL and NPS, survival was significant higher in patients with complete PS resolution. Despite HL treatment, NPS may be irreversible due to cytoxic neuronal loss; thus, timely recognition of PS is essential in providing effective therapy, requiring oncologic treatment as shown in our series of patients who only achieved complete resolution of NPS with HL remission.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18